Pharmaceutical Technology
MAY 19, 2023
Rinvoq is a major pillar in AbbVie’s plan to stem revenue drops once biosimilars to its behemoth Humira (adalimumab) enter the market on a sustained basis this year. Other notable recent approvals for Rinvoq came in ulcerative colitis, another inflammatory bowel disease, by the FDA in March 2022 and then the European Commission in July 2022.
Pharmacy Times
JUNE 26, 2025
In an interview with Pharmacy Times , Shaji Kumar, MD, consultant and research chair of the Division of Hematology in the Department of Internal Medicine at Mayo Clinic, discussed emerging data from the phase 2 RedirecTT-1 study (NCT04586426).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 3, 2022
Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs. The post Civica plans shake-up of insulin sector with low-cost biosimilars appeared first on. Cheaper options are meanwhile becoming available.
Pharmacy Times
JUNE 16, 2025
Mayo Clinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. News release. June 6, 2025. Accessed June 16, 2025. Atopic Dermatitis. News release. May 15, 2024. Accessed June 16, 2025. Ferruggia K. Pharmacy Times.
Pharmacy Times
JUNE 20, 2025
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)
Pharmacy Times
JUNE 23, 2025
This act…allowed a pathway for manufacturers to create a ‘copy’ of a licensed patent product to make it cheaper and more discounted,” Soefje, director of pharmacy cancer care services and associate professor of pharmacy at Mayo Clinic in Rochester, Minnesota, said at the HOPA conference.
Pharmacy Times
JUNE 19, 2025
1 "Immunotherapy given neoadjuvantly may not be the appropriate treatment strategy for patients with high fusion,” said Kaushal Parikh, MD, from Mayo Clinic. “In Mandatory ALK fusion testing should become part of the standard of care to better personalize treatments to a patient’s specific ALK variant.
Expert insights. Personalized for you.
105 
Let's personalize your content